Study of Recombinant Human B Lymphocyte(RC18) Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)
A Phase III, Placebo-Controlled ,Multi-Center, Randomized, Double-Blind, Dose-exploring Trial of RC18,a Recombinant Human B Lymphocyte Stimulating Factor Receptor-Antibody Fusion Protein in Subjects With Systemic Lupus Erythematosus (SLE).
Sponsor: RemeGen Co., Ltd.
A PHASE3 clinical study on Systemic Lupus Erythematosus, this trial is completed. The trial is conducted by RemeGen Co., Ltd. and has accumulated 9 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jun 2023 — Jul 2024 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Feb 2022 — Jun 2023 [monthly]
Active Not Recruiting PHASE3
-
Oct 2021 — Feb 2022 [monthly]
Active Not Recruiting PHASE3
▶ Show 4 earlier versions
-
May 2021 — Oct 2021 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Jan 2021 — May 2021 [monthly]
Recruiting PHASE3
-
Jan 2020 — Jan 2021 [monthly]
Recruiting PHASE3
-
Oct 2019 — Jan 2020 [monthly]
Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- RemeGen Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .